Lantern Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Lantern Pharma Inc.'s 2023 Annual Meeting of Stockholders held on June 16, 2023. The company is a Delaware corporation with its principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol LTRN.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
Three primary matters were submitted to a vote of security holders:
- Election of Directors: All six nominees were elected to serve until the 2024 Annual Meeting. The nominees are Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein. Significant broker non-votes (2,805,241 shares) were recorded for each director election.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to increase the number of shares available for issuance under the 2018 Equity Incentive Plan by an additional 250,000 shares. The vote was 4,145,520 For, 96,840 Against, and 14,138 Abstain.
- Ratification of Auditors: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 7,015,460 For, 41,115 Against, and 5,164 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Confirmation that the 250,000 share increase to the Equity Incentive Plan has been formally implemented in the company's cap table.
- Review of the full proxy statement to understand the specific qualifications of the newly elected directors.
- Verification of the high volume of broker non-votes (approx. 2.8 million shares) and their impact on the effective voting power of beneficial owners.
- Confirmation that EisnerAmper LLP has accepted the appointment for the 2023 fiscal year.